Chemical Intermediate Vorinostat CAS 149647-78-9 Vorinostat

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-Vorinostat
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Vorinostat
• Name: Vorinostat Powder
• Appearance: White Powder
• Colour: White
• Grade: Pharmaceutical Grade
• Assay: >99%
• Application: API
• Specific: COA
• Test Method: HPLC
• Density: 1.174
• CAS: 149647-78-9
• Mf: C14h20n2o3
• MW: 264.3202
• Melting Point: 161-162c
• Boiling Point: 760mmhg
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS-Vorinostat
• Origin: Xian
• Production Capacity: 500kg/Month

Product Description

Chemical Intermediate Vorinostat CAS 149647-78-9 Vorinostat

Product Description

Product Details

Product Name	Vorinostat
Appearance	Vorinostat Powder
Assay	>99%
MW	264.3202
MF	C14H20N2O3
Melting point	161-162C
Boiling point	760mmHg

Vorinostat is a targeted anti-tumor drug that induces tumor cell cycle arrest, apoptosis, and differentiation by inhibiting histone deacetylase (HDAC1/2/3/6/7/11).
Indications and approvals
Main purpose: To treat recurrent/refractory cutaneous T-cell lymphoma (CTCL), especially in cases where other therapies are ineffective.
Approval history: In 2006, it became the first FDA approved HDAC inhibitor anti-cancer drug.
Clinical characteristics
Dosage form: Oral capsules, suitable for patients with advanced CTCL accompanied by skin invasion.
Research and development background: Developed by Merck, it belongs to the targeted drugs of epigenetic regulation.

Application&Function

Vorinostat is a histone deacetylase (HDAC) inhibitor, whose drug effects mainly include the following aspects:

Mechanism of action

By chelating zinc ions at the catalytic site of HDAC with hydroxamic acid groups, histone deacetylase activity is inhibited, leading to high acetylation of histones and non histones (such as p53 and alpha tubulin).
High acetylation of histones can upregulate cyclin dependent kinase p21 and induce G1 phase cell cycle arrest; Simultaneously, by regulating non histone proteins such as heat shock protein 90, tumor cell proliferation is inhibited and apoptosis is promoted.
It has a strong inhibitory effect on HDAC1/2/3 (type I) and HDAC6 (type II), and in vitro experiments have shown that the half inhibitory concentration (IC50) for various cancer cells is as low as the nanomolar level.

Indications

Mainly used for the treatment of recurrent, drug-resistant, or advanced cutaneous T-cell lymphoma (CTCL), especially suitable for second-line treatment after the failure of two systemic drug therapies.
Having the ability to penetrate the blood-brain barrier, it may expand its potential applications in other central nervous system tumors.

In vitro activity

In MES-SA cells, a concentration of 3 μ M can significantly inhibit cell growth, induce p21WAF1 expression and apoptosis.
The IC25 values for the neuroblastoma cell lines SK-N-SH and SK-N-Be (2) C were 1 μ M and 0.5 μ M, respectively.

Pharmacokinetic characteristics

As an oral small molecule drug, its pan HDAC inhibitory properties (IC50=10 nM) endow it with broad-spectrum anti-tumor activity.

Specification